In-depth analysis of molecular regulatory networks in cancer holds the promise of improved knowledge of the pathophysiology of tumor cells so that it will become possible to design a detailed molecular tumor taxonomy. This knowledge will also offer new opportunities for the identification and validation of key molecular tumor targets to be exploited for novel therapeutic approaches. Some signaling proteins have already been identified as such, e.g. c-Myc, Cyclin D1, Bcl-XL, kinases and some nuclear receptors. This has led to the successful development of a few function-modulatory drugs (Glivec, SERM, Iressa), providing proof-of-principle of the validity of this approach. Further developments are likely to derive from "-omic" approaches, aimed at the understanding of signaling networks and of the mechanism of action of newfound lead molecules. High-throughput screening of small drug-like molecules from combinatorial chemical libraries or from microbial extracts will identify novel, "intelligent" drug candidates. An additional medicinal chemistry strategy (via 40-50 unit rosary-bead chains) has the potential to be much more effective than small molecules in interfering with protein-protein interactions. This may lead to considerably higher selectivity and effectiveness compared with historical approaches in drug discovery. (Int J Biol Markers 2003; 18: 57-61)
Several antineoplastic agents, still currently in use for the treatment of patients, are 40-50 years old (1) . Change and innovation has been scanty in terms of new drug families, i.e., drugs possessing a new or different mechanism of action.
Examples are those of nitrogen mustards-alkylating agents, which were developed during World War II. Farber and coworkers reported temporary remissions of acute leukemias in children treated with aminopterin in 1948. 5-fluorouracil was synthesized by Heidelberger and coworkers in 1957. Noble and colleagues found in 1958 that an alkaloid extracted from Vinca rosea was able to induce granulocytopenia and bone marrow suppression.
Traditional antineoplastic chemotherapeutic agents belong to several different families: alkylating agents; antimetabolites; stabilized intercalating agents; topoisomerase II inhibitors; topoisomerase I inhibitors; and poisons of the mitotic spindle. However, all of these families belong to a single superfamily, that of indiscriminate poi-sons of the cell replication machinery.
Poisons of the replication machinery have intrinsic limitations in discriminating between actively proliferating (& transcribing/translating) cancer cells and actively proliferating (& transcribing/translating) normal cells.
There exists a conceptual relationship between the issues raised above and the following epidemiological data:
• Overall, an average of 45-50% of patients still die of cancer even in the best cancer centers. • Surgery still accounts for at least 80% of "cures", while less than 20% of additional "cures" can be attributed to medical treatment alone or (mainly) as adjuvant therapy. In particular, cancer chemotherapy only "cures" about 10% of all cancers. • When a "cure" is not achievable (advanced cancer), the average prolongation of survival due to cancer chemotherapy is often minimal, if any. An old shortcut proposed about half a century ago (and unchanged thereafter) borrowed its philosophy from the strategy applied to the discovery of antibacterial drugs: to screen large numbers of heterogeneous molecules against rapidly growing bacterial cultures; active compounds will display selective toxicity for bacterial cells and little activity against dividing or quiescent mammalian cells.
Adapted to cancer cells this old shortcut became: to screen hundreds of thousands of chemicals against rapidly dividing cancer lines, hoping that active compounds would display selective toxicity for cancer cells. In general, unfortunately, this was not the case, especially for the toxicity commonly experienced by rapidly dividing normal cells.
For example, the US National Cancer Institute (NCI) has screened approximately one million compounds in a period of about 40 years. Other laboratories around the world have screened significant numbers of candidate molecules. However, essentially only poisons of the replication machinery have emerged from these extensive "cell-as-the-primary-target" screenings.
These findings indicate that the holistic approach of using a rapidly proliferating cancer cell as a primary target for screening large numbers of compounds with unknown mechanisms of action should be abandoned.
A new approach to the classification of antineoplastic drugs (2) has been proposed: • class A: poisons of the replication machinery (low hierarchical levels within the signaling network); • class B: inhibitors of signaling proteins (that "drive-sustain" malignancy in specific classes of tumors) (higher hierarchical levels within the signaling network).
A new class of antineoplastic agents
Systematic efforts aimed at the synthesis of class B drugs started only a few years ago. We are still far away from detailed knowledge and understanding of the cell's signaling modules and protein/gene networks. Therefore, even a strategy for finding more selective antineoplastic drugs as outlined here is still a shortcut, although a much more sophisticated one than the predominant strategies of the last five to six decades. Success has been obtained in a few instances (see the case of the selective Bcr-Abl kinase inhibitor Glivec in chronic myeloid leukemias). However, this paradigm is still a working hypothesis in various other malignancies.
Strategies to identify novel, "intelligent" anticancer drugs a) Search for lead molecules active against a selective group of molecular targets
Approaches of combinatorial chemical libraries and high-throughput screening are being used to find druglike molecules capable of selective interaction with their targets. Similarly, libraries of molecules from microorganisms (or other living organisms, e.g. marine animals and plants) have led to the isolation of interesting, unusual lead compounds. More innovative strategies are also be-ing implemented.
A recent comment (3) is illuminating. After reporting about the successful search for small drug-like selective inhibitors of kinases at the level of the ATP pocket, the author adds: "Most attempts to identify small molecules that disrupt protein-protein interactions have been unsuccessful", and further on: "Compounds that disrupt these interactions may need to be relatively large and complex, because the binding surfaces between protein subunits often consist of multiple interactions dispersed over a wide area […] Effective compounds may therefore have to resemble natural products or peptides rather than the types of molecules typically contained in chemical libraries." Analogous comments were published in the FASEB Journal, 2001 (4) . The relevance and difficulties of developing antineoplastic drugs aimed at disrupting protein-protein interactions have recently been highlighted also by James E. Darnell, 2002 recipient of the Albert Lasker Award (5) . Summarizing: companies prefer to target polar active sites/pockets that can be easily fitted with small drug-like molecules, but "What is the benefit to medicine, in all the twenty-first century promise of proteomics, if we cannot selectively inhibit protein-protein interactions?"
It has been calculated that it would be useful to obtain molecules able to "see" at least 600-2500 Å 2 of the surface of a target protein, instead of the usual 25-100 Å 2 "seen" by a typical, more compact and smaller drug-like molecule (around 500 Daltons). Thus, larger sequence motifs of proteins involved in cross-talks with target signaling proteins should also be explored. It should be noted that peptidomimetic (rosary-bead chains) molecules up to 5000-6000 Daltons (~fifty beads) can be synthesized (and scaled-up) relatively easily. Recent progress in computer modeling and analysis of protein structure, combined with technological progress in stepwise solid-phase peptide-like synthesis, permits to rapidly generate and screen small peptidomimetic combinatorial libraries, constructed around the initial inspiring peptidic motif (6, 7) .
Seminal work on the construction of a Myc inhibitor peptide (8) and more recent follow-up findings (4) are examples along these lines. A retro-inverso (RI) conformation of Int (RI-Int or the like) (internalization sequence from Antennapedia) (4) can be used effectively to internalize five-ten times longer, linked peptides. Additional unpublished evidence strongly confirms the sequence and structure specificity of these novel peptide-like molecules (Annex A).
Therefore, it seems possible to achieve a "broader vision of the target". Relatively small peptidomimetic combinatorial libraries can be implanted over the scaffold of a lead peptidic motif suggested by nature (7) and can be guided by intelligent reasoning and adequate computer modeling.
At the level of the molecular phenotype, we can define cancer as pathology of cross-talks among signaling proteins. Thus, a key point in the development of novel therapeutic strategies is the choice of signaling proteins as reductionist targets for primary screening, rather than the global behavior of a rapidly proliferating cancer cell.
Side effects affecting the normal signaling functions of these proteins are expected. However, recent experience, especially with tyrosine kinase inhibitors working in the ATP pocket of this class of proteins, suggests that cancer cells with excess functioning of a tyrosine kinase tend to be hypersensitive to the corresponding inhibitors. Important therapeutic indexes could thus be achieved, not only in experimental models but also in specific human cancers.
The case of Glivec is of interest. A key aspect of this drug is its specificity for "the" key molecular alteration of chronic myelogenous leukemias (fusion of Bcr to Abl driven by the t(9;22) translocation. However, recent clinical reports on the use of inhibitors of c-ErbB-2 receptor, epithelial-GF receptor and endothelial-GF receptor in mammary and lung cancers call for caution in assuming a direct link between overexpression and increased sensitivity. The underlying molecular disorder seems much more subtle. Perhaps it will be easier to achieve the production of good signaling protein inhibitors than the knowledge that will guide their appropriate use, alone or in combination, for a specific molecular disorder. Hitting the excess of function of more than one signaling-protein at a time in an individual tumor could improve these results and lead to persistent regression, or at least transformation of advanced cancer in indolent chronic disease.
We may therefore envisage the development of ad hoc cocktails for individual tumors, rather than protocols for an average tumor class. Microarrays and highthroughput technologies (for parallel DNA sequencing, mRNA levels and protein levels) will permit large-spectrum molecular diagnoses of individual cancers, articulated in clusters of closely related subtypes.
b) "-omic" approaches (mRNA and protein levels) aimed at understanding the mechanism of action of new lead molecules
The difficulty of analyzing the selectivity of new lead molecules against signaling protein targets is easy to imagine. Performing this type of analysis with classical biochemical technologies appears very labor-intensive and is probably unrealistic in particular cases. An alternative approach is the analysis of the changes taking place in large aggregates of data, after treatment of a whole cell with a given molecule.
Several points are of relevance in this context. First of all classical pharmacological parameters: dosages, treatment schedules, and time intervals between treatment and observation of response. Early changes in mRNA or protein expression patterns have a different significance compared with later events: ideally, a small bidimension-al matrix of (sequential-time-analysis) x (dosage-analysis) should be investigated, possibly using a selected subset of genes. The selection of an appropriate set of genes for this approach will greatly benefit from the improvement of our knowledge about signaling networks around our signaling protein targets and in our selected target cells over time.
Key questions at this stage are: Which target cells will give us more information about the effects of candidate compounds and which tumor targets are best treated with those compounds? Most likely a panel of different cells will be required for this purpose. It should be noted that the relationship between the molecular pathology of the signaling network and drug sensitivity could be much more significant for inhibitors of signaling proteins than for poisons of the replication machinery. Techniques are now available to investigate these relationships.
Analysis of the tumor transcriptome on DNA microarrays
Large sets of genes transcribed by individual breast tumors are analyzed by hybridization to sets of oligonucleotides or cDNAs immobilized to glass slides (9) . RNA extracted from frozen tumor samples is reverse-transcribed, labeled with appropriate fluorochromes (Cy3, Cy5, Alexas) and hybridized to the DNA arrays on the slides. Signals are collected by a dedicated scanning device. Competition with RNA from normal tissues allows to determine what genes are overexpressed or shut off in cancer tissues. Cluster analysis programs and dendrogram representations allow to determine what genes are associated with cancer progression (10, 11) or with sensitivity/resistance to therapy (12) .
Analysis of the tumor proteome on 2D gels and by mass spectrometry
Two-dimensional gels can be utilized to reliably separate tumor proteins by size and isoelectric point (13) . Gels are stained with silver nitrate or fluorescent dyes, and the relative amounts of each protein (spot) in the gel are quantified (images of all the gels are acquired and stored, highly reproducible gel runs can be achieved and spotby-spot comparison can be performed). Frozen tumor samples are analyzed by histopathology and macroscopically dissected, if necessary, to isolate tumor tissue. Tumor homogenates are prepared and analyzed by 2D gels.
The results obtained may lead to the identification of significant aggregations of biological determinants connected with tumor relapse and resistance to therapy (14) . Novel genes associated with tumor progression may emerge. For example, a number of 2D protein spots may be correlated with the aggressiveness of the disease. MALDI-TOF peptide fingerprinting or amino acid sequencing can identify known proteins, provide sequence information on the unknown ones (15) , and identify the corresponding genes from human genome sequence databanks.
c) Bioinformatics: molecular interaction maps (modules around target proteins)
Bioinformatic analysis will be crucial to identify the connectivity between the different parameters measured above. Molecular interaction maps for Myc and interacting proteins are being developed, with emphasis on their role in the regulation of cell mass increase and cell proliferation. The specific aim is to organize the currently available information on protein-protein interactions, protein modifications, gene transcription controls, protein degradation and cell compartment translocation processes. The interactions are mapped, annotated, and referenced in a manner similar to that presented in (16) . This assembled knowledge will be used to reveal the network structure of the Myc-related controls on cell mass growth and cell proliferation, and will serve as a resource for the interpretation of functional data, formulation of hypotheses for experimental testing, and identification of new molecular targets for therapeutic intervention.
Desirable characteristics of the circuitry of these signaling maps are: self-consistent and clearly defined symbol conventions, easy location of molecular species, and efficient access to further information and references. The thorny task of extracting something meaningful from molecular maps will give us a lot to work on. However, the potential is there to efficiently tap into an immense wealth of molecular, biochemical and structural data. We share the feeling of Tony Hunter (17) that this is go-ing to be one of the major research themes for the incoming generation of investigators. Molecular interaction maps are going to play a crucial role as a support and guide to the construction of "finalized microarrays" as collections of cDNA specifically and closely linked to the signaling molecule of interest. These will be most appropriate and convenient to investigate the downward effects of a lead molecule, as a "bona fide" inhibitor of a given signaling protein target.
